The PennZone

BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic^® in Ocudose^®) and has begun commercialization activities.

Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:

• the preservative in Timolol Maleate Ophthalmic Solution, USP,
• benzalkonium chloride, or
• when the use of a preservative-free topical medication is advisable.

"We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio," stated Daniel Carbery, President and CEO of Amring. "We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines."

More on The PennZone

• First Generation and TechniCom Leadership Appointments Usher in a Bright Future
• Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
• GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
• Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
• What are the signs of an AC refrigerant leak?

About Amring Pharmaceuticals Inc.

Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

Safe Harbor

This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

More on The PennZone

• The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
• Philadelphia Homeowners Now Have a Faster Way to Sell Their House Without Agents or Repairs
• The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
• Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
• Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request

Contacts

Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com

---

Show All News | Report Violation